Healthcare / Medical DistributionJakarta
$189.00
+1.00 (+0.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-113.2B · quality 29.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$240.8B
P/E
6.3x
↓EV/EBITDA
7.2x
↓ROE
12.2%
↑Gross Margin
8.8%
↓Debt/Equity
2.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.7%
FCF CAGR
—
FCF margin
0.9%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.11T · net income $38.47B · FCF $39.00B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4109.81B | $4109.81B | $3916.86B | $3363.52B | $3200.83B |
| Net Income | $38.47B | $38.47B | $16.93B | $33.09B | $24.46B |
| EBITDA | $137.23B | $137.23B | $120.06B | $124.51B | $91.48B |
| EPS | — | — | 13.29 | 25.97 | 19.20 |
| Gross Margin | 8.8% | 8.8% | 8.5% | 8.7% | 8.4% |
| Operating Margin | 2.8% | 2.8% | 2.5% | 3.1% | 2.4% |
| Net Margin | 0.9% | 0.9% | 0.4% | 1.0% | 0.8% |
| Balance Sheet | |||||
| Debt/Equity | 2.57 | 2.57 | 3.00 | 2.56 | 2.19 |
| Current Ratio | 1.11 | 1.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $39.00B | $39.00B | $-139.61B | $-113.17B | $-124.63B |
| Returns | |||||
| ROE | 12.2% | 12.2% | 6.0% | 11.9% | 9.4% |
| Valuation | |||||
| P/E | 6.30 | 6.30 | 9.93 | 6.24 | 13.44 |
| EV/EBITDA | 7.20 | 7.20 | 8.01 | 6.89 | 9.52 |
| P/B | 0.76 | 0.76 | 0.60 | 0.74 | 1.27 |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 16.5% | 5.1% | — |
| EPS Growth | — | — | -48.8% | 35.3% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+47.6%
Start / end P/E
n/dx → n/dx
EPS bridge
13.29 → n/d
Residual
+46.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.